Worth reading
40Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
850
¥100 million (fiscal 2028 net sales target)Wording
Conditional
How definitive the wording is.Items stated in the management plan
FormulatedNet SalesNot disclosed → 850 Hundreds of millions of yen
Only the target level is shown because the current level for comparison was not provided.Statements about the use of capital
Self-assessment of PBR and share priceAddressing the improvement of PBR as an important management issuePBR is a measure of how many times the share price is the book value per share.
Key initiatives
01Domestic prescription pharmaceuticals business — Strengthening earnings power through further expansion of the specialty fields —
02Drug discovery business — Promoting global expansion —
03Global business — Strengthening the business platform through the launch of a new plant —
04Animal health business — Expanding the business through new product launches and overseas expansion —
05Testing and around-the-pill business — Expanding the testing business by leveraging trace analysis and extending into pharmaceutical-adjacent fields —
06Financial strategy — Advancing management with a focus on the cost of capital —
07Strengthening the management platform — Strengthening the management infrastructure for executing the strategy —
Non-financial targetsIndicator name Percentage of outside directors / Target value More than half / Timing In conjunction with the transition from a company with an Audit & Supervisory Board to a company with an Audit & Supervisory Committee
| Item | Details |
|---|---|
| Plan name | Long-Term Vision “ASKA VISION 2035” and “Medium-Term Management Plan 2028” |
| Plan period | ASKA VISION 2035: Long-term vision looking toward 2035 (10 years from now) / Medium-Term Management Plan 2028: Fiscal 2026–fiscal 2028 |
| Progress against the plan | Formulated |
| Sales Target | Not disclosed → 850 Hundreds of millions of yen |
| Self-assessment of PBR and share price | Addressing the improvement of PBR as an important management issue |
| Non-financial targets | Indicator name Percentage of outside directors / Target value More than half / Timing In conjunction with the transition from a company with an Audit & Supervisory Board to a company with an Audit & Supervisory Committee |
| Key initiatives | Domestic prescription pharmaceuticals business — Strengthening earnings power through further expansion of the specialty fields —, Drug discovery business — Promoting global expansion —, Global business — Strengthening the business platform through the launch of a new plant —, Animal health business — Expanding the business through new product launches and overseas expansion —, Testing and around-the-pill business — Expanding the testing business by leveraging trace analysis and extending into pharmaceutical-adjacent fields —, Financial strategy — Advancing management with a focus on the cost of capital —, Strengthening the management platform — Strengthening the management infrastructure for executing the strategy — |
| Publication date | 23 March 2026 |
Items this document does not state (17)
Operating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalTotal investment planInvestment amount by sectorSegment targetPlan assumptionsResults under the previous planReason for revision or withdrawalSize of the Target MarketRisks identifiedDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To establish a sustainable earnings base by achieving sustained growth and contributing to society, while balancing steady growth in existing businesses with the development of foundations for future growth.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.